CVS Health (CVS)
International Stocks
Buy
Jim Kramer shares his view on CVS Health's situation.
J
Jim Kramer2h* Does not constitute investment advice
Yükleniyor...
Yükleniyor...
How recommendation distribution changed over time
Only 1 analyst has covered this - limited data
Analysts are largely in agreement
Evaluated within the last 7 days
One-directional consensus
Stable interest level
Chronological view of analyst recommendations for this asset
The speaker analyzes the company's fourth-quarter performance, the reiteration of profit expectations, and the recovery trend in the share price.
Yahoo FinanceThe speaker examines the regulatory news leading to the worst day in a decade for CVS shares and its medium-term implications.
CNBC TelevisionThe speaker commits to allowing lower-cost medication options to count towards patient deductibles. This signals a potential shift in pricing models and deductible structures in response to legislative pressure regarding drug costs.
Yahoo FinanceThe speaker evaluates the company's dividend yield and managerial improvements by comparing them with UnitedHealth.
CNBC TelevisionThe speaker evaluates the recovery process under the new CEO and the market advantage created by competitors downsizing.
CNBC TelevisionThe speaker analyzes the rotation into non-tech momentum stocks and the performance of this specific equity.
CNBC TelevisionThe speaker evaluates CVS's performance as a beneficiary of trends in drug spending and business turnarounds, noting its strategic exit from the marketplace segment to reduce policy exposure.
CNBC TelevisionThe speaker analyzes the pressure from healthcare cost inflation and the company's future guidance expectations.
Yahoo FinanceThe CEO of CVS Health evaluates the company's long-term earnings targets, including a projected 15% compound annual growth rate by 2028. He examines the strategic shift towards transforming healthcare delivery through technology, emphasizing improvements in operating efficiency, the successful turnaround of Aetna, and the return to growth in the retail sector, alongside the expanding role of pharmacists in community care.
CNBC TelevisionThe speaker examines the company's integration of new AI technologies into its operations and its potential effects on competitive advantage and stock performance.
CNBC TelevisionJim Kramer shares his view on CVS Health's situation.
* Does not constitute investment advice
The speaker analyzes the company's fourth-quarter performance, the reiteration of profit expectations, and the recovery trend in the share price.
* Does not constitute investment advice
The speaker examines the regulatory news leading to the worst day in a decade for CVS shares and its medium-term implications.
* Does not constitute investment advice
The speaker commits to allowing lower-cost medication options to count towards patient deductibles. This signals a potential shift in pricing models and deductible structures in response to legislative pressure regarding drug costs.
* Does not constitute investment advice
The speaker evaluates the company's dividend yield and managerial improvements by comparing them with UnitedHealth.
* Does not constitute investment advice
The speaker evaluates the recovery process under the new CEO and the market advantage created by competitors downsizing.
* Does not constitute investment advice
The speaker analyzes the rotation into non-tech momentum stocks and the performance of this specific equity.
* Does not constitute investment advice
The speaker evaluates CVS's performance as a beneficiary of trends in drug spending and business turnarounds, noting its strategic exit from the marketplace segment to reduce policy exposure.
* Does not constitute investment advice
The speaker analyzes the pressure from healthcare cost inflation and the company's future guidance expectations.
* Does not constitute investment advice
The CEO of CVS Health evaluates the company's long-term earnings targets, including a projected 15% compound annual growth rate by 2028. He examines the strategic shift towards transforming healthcare delivery through technology, emphasizing improvements in operating efficiency, the successful turnaround of Aetna, and the return to growth in the retail sector, alongside the expanding role of pharmacists in community care.
* Does not constitute investment advice
The speaker examines the company's integration of new AI technologies into its operations and its potential effects on competitive advantage and stock performance.
* Does not constitute investment advice